Items where Author is "Tilly, H."

Conference or Workshop Item

Held, G. and Poeschel, V and Altmann, B. and Illmer, T. and Andre, M. and Dreyling, M. and Maisonneuve, H. and Tilly, H. and Mayer, S. and Casasnovas, R. -O and Le Gouill, S. and Offner, F. C. and Cartron, G. and Kerkhoff, A. and Weber, T. and Hoffmann, J. and Ziepert, M. and Klapper, W. and Itti, E. and Hellwig, D. and Natchkebia, G. and De Leval, L. and Rosenwald, A. and Haioun, C. and Dercle, L. and Gaulard, P. and Houot, R. (2021) Nivolumab in combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-cell Lymphoma: Preliminary results of the experimental arm of the NIVEAU trial. In: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 01.-04. Oktober 2021, Berlin, Germany.

Thurner, L. and Poeschel, V. and Haioun, C. and Houot, R. and Gaulard, P. and Molina, T. and Rosenwald, A. and Andre, M. and Hoffmann, J. and Dreyling, M. and Casasnovas, O. and Maisonneuve, H. and Tilly, H. and Illmer, T. and Mayer, S. and Kirchen, H. and La Rosee, P. and Loeffler, M. and Ziepert, M. and Altmann, B. and Held, G. (2020) Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx. In: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020, Virtuell.